Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Psychiatry Cardiology Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Anesthesiology & Pain Medicine Pulmonology & Critical Care Physical Medicine & Rehab Nephrology Emergency Medicine Urology Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Type 1 diabetes mellitus

Part of Type 1 Diabetes

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Type 1 diabetes mellitus

350 trials tracked for Type 1 diabetes mellitus: 101 in phase 3 or 4 and 46 with published results. The most-cited published study has 492 citations.

350Trials tracked

101Phase 3 & 4

0Recruiting

46With published results

Phase distribution

Phase 4 25 Phase 3 76 Phase 2 64 Phase 1 39 Other / NA 146

Phase 3 The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus Completed · 492 cited
Phase 3 Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) Completed · 363 cited
Phase 3 Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) Completed · 361 cited
Phase 3 REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL) Completed · 354 cited
Phase 3 The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes Completed · 340 cited
Phase 3 The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes Completed · 259 cited

Show 44 more trials

Phase 3 Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab Completed · 252 cited
Phase 3 Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy Completed · 231 cited
Phase 3 Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus Completed · 212 cited
Phase 3 A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes Completed · 207 cited
Phase 3 A Study in Participants With Type 1 Diabetes Mellitus Completed · 186 cited
Phase 3 Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy Completed · 186 cited
Phase 3 A Study in Participants With Type I Diabetes Mellitus Completed · 186 cited
Phase 3 Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes Completed · 177 cited
Phase 3 Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease Completed · 124 cited
Phase 3 Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes Completed · 121 cited
Phase 3 A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6) Completed · 107 cited
Phase 3 Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes Completed · 79 cited
Phase 3 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Completed · 79 cited
Phase 3 Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes Completed · 79 cited
Phase 3 The Bihormonal iLet Bionic Pancreas Feasibility Study Completed · 71 cited
Phase 3 Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes Completed · 71 cited
Phase 4 Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study Completed · 68 cited
Phase 3 Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes Completed · 67 cited
Phase 3 Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes Completed · 56 cited
Phase 3 A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects Completed · 54 cited
Phase 3 Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes Completed · 50 cited
Phase 4 Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D) Completed · 37 cited
Phase 3 FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump Completed · 37 cited
Phase 3 Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine Completed · 33 cited
Phase 3 Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics Completed · 32 cited
Phase 3 Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus Completed · 27 cited
Phase 4 Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients Completed · 23 cited
Phase 3 G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes Completed · 22 cited
Phase 3 Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics Completed · 22 cited
Phase 3 A Study of LY900014 in Participants With Type 1 Diabetes Completed · 14 cited
Phase 3 A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003) Completed · 9 cited
Phase 3 G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes Completed · 8 cited
Phase 3 Mylan Insulin Aspart Study Completed · 8 cited
Phase 4 Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. Completed · 6 cited
Phase 4 Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings Completed · 5 cited
Phase 3 A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus Completed · 5 cited
Phase 4 Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency Completed · 3 cited
Phase 3 Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine Completed · 3 cited
Phase 3 A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Completed · 3 cited
Phase 3 Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults Completed · 2 cited
Phase 4 Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon Completed
Phase 4 Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus Completed
Phase 4 Sitagliptin Dose Determination Study Completed
Phase 4 Detemir: Role in Type 1 Diabetes Completed

Showing the 50 most-cited and recently-updated of 350 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Type 1 diabetes mellitus: what the trials found

Several insulin formulations and delivery systems have been evaluated for their impact on glycemic control. Insulin glargine (300 U/ml) demonstrated non-inferiority in time in range (TIR) of 70-180 mg/dL compared to a reference, while also showing significant improvements in the coefficient of variation (CV%) ¹⁰. A separate study on insulin glargine showed consistent results for both time in range and time in serious hypoglycemia ¹². Insulin degludec was associated with significantly improved time in range (70-140 mg/dl and 70-180 mg/dl) and lower mean glucose levels compared to baseline ¹¹.

Advanced insulin delivery systems, such as the Tandem t:slim X2 with HCL or PLGS, showed low rates of hypoglycemia (under 54 mg/dL) and high percentages of time in range ⁹. The use of Technosphere insulin was associated with increased time in range, reduced post-prandial glucose excursions, and decreased glucose variability ⁸. Rapid-acting insulin combined with rHuPH20 pre-treatment demonstrated consistent times to reach specific glucose reduction targets ¹⁸.

Other pharmacological interventions include sitagliptin, which was associated with better targeted blood glucose levels ²¹, and SGLT2 inhibitors, which were shown to result in lower capillary blood beta-hydroxybutyrate levels during outpatient care ¹³. Rapid-acting insulin options like glulisine and Fiasp were evaluated for post-prandial management and time in range respectively [14, 17]. Afrezza was also assessed regarding hypoglycemia rates ¹⁵.

Recent results — preliminary, needs further review

Control-IQ technology 2.0 showed low percentages of time below 54 mg/dL (0.1% to 0.2%) and moderate time in range between 70-140 mg/dL (~51-53%) ¹.
The EnMPC AP Controller demonstrated high time in range (81%) and zero percent of time below 54 mg/dL ³.
Omnipod 5 System showed a range of time in range results (39.42% to 65.26%) with low rates of hypoglycemia ⁵.
The t:slim X2 with Tandem Freedom Algorithm demonstrated high time in range (~56-61%) and very low rates of hypoglycemia ⁷.
Continuous Glucose Monitoring (CGM) was associated with a significant reduction in Hemoglobin A1c over 3 months (-0.9, p=0.03) and a reduction in depression scores ⁶.

For the clinician treating this condition

Multiple insulin formulations, including glargine and degludec, have demonstrated consistent efficacy in maintaining time in range (TIR) and reducing glucose variability.
Advanced automated insulin delivery systems and specific technologies (e.g., Control-IQ, EnMPC, Tandem Freedom Algorithm) consistently demonstrate low rates of hypoglycemia while maintaining target ranges.
Continuous Glucose Monitoring is associated with significant improvements in both clinical markers (HbA1c) and patient psychological well-being.

AI synthesis of 14 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

1 2 Next ›

Research across Type 1 Diabetes

Related studies from across the Type 1 Diabetes family.

T1D MAPS polygenic score improves discrimination in non-EUR populations compared to T1D GRS2

Diabetes & Endocrinology Meta-analysis

T1D MAPS polygenic score improves discrimination in non-EUR populations compared to T1D GRS2 New genetic scores improve risk prediction for type 1 diabetes

This meta-analysis evaluates the predictive performance of multiple polygenic scores for Type 1 Diabetes. The T1D MAPS score demonstrated si…

A new genetic scoring system shows better accuracy in predicting type 1 diabetes risk for people of diverse backgrounds.

medRxiv Sep 9, 2026

Automated insulin delivery systems improve time in range and reduce distress in older adults with type 1 diabetes

Diabetes & Endocrinology Meta-analysis

Automated insulin delivery systems improve time in range and reduce distress in older adults with type 1 diabetes Automated insulin delivery systems help older adults with type 1 diabetes

This meta-analysis of 8,765 adults aged 60 years and older with type 1 diabetes indicates that automated insulin delivery systems are associ…

New data shows automated insulin delivery systems can improve blood sugar control and reduce stress for older adults living with type 1 diab…

Financial incentives and web coaching significantly reduce HbA1c in young adults with Type 1 Diabetes

Diabetes & Endocrinology RCT

Financial incentives and web coaching significantly reduce HbA1c in young adults with Type 1 Diabetes Financial rewards and coaching help young adults manage type 1 diabetes

This randomized trial of 300 young adults with Type 1 Diabetes found that a combination of financial incentives and web coaching significant…

A new trial shows that combining financial incentives with web coaching helps young adults with type 1 diabetes lower their A1c levels.

Older patients with Type 1 Diabetes are more likely to be permitted to fast during Ramadan

Diabetes & Endocrinology Guideline

Older patients with Type 1 Diabetes are more likely to be permitted to fast during Ramadan Arab youth with Type 1 Diabetes navigate fasting during Ramadan

This cross-sectional study explores the experiences of Arab children, adolescents, and young adults with Type 1 Diabetes during Ramadan. Fin…

New data explores how Arab children and young adults manage Type 1 Diabetes while fasting during the holy month of Ramadan.

Frontiers Aug 26, 2026

Discharge planning for diabetes is multicomponent but lacks consistent outcomes and long-term follow-up

Primary Care & Family Medicine Meta-analysis

Discharge planning for diabetes is multicomponent but lacks consistent outcomes and long-term follow-up Multicomponent Discharge Planning Helps Manage Diabetes After Hospital Stays

This scoping review of 20 studies maps discharge planning services for adults with diabetes transitioning from hospital to home. Interventio…

New research highlights how comprehensive discharge plans can help patients with Type 1, Type 2, and gestational diabetes manage their healt…

Frontiers Aug 21, 2026

Finerenone reduces UACR by 25% in adults with type 1 diabetes and CKD

Diabetes & Endocrinology RCT

Finerenone reduces UACR by 25% in adults with type 1 diabetes and CKD Trial shows finerenone reduces kidney markers in type 1 diabetes

This randomized controlled trial of 242 adults with type 1 diabetes and chronic kidney disease found that finerenone reduced UACR by 25% ove…

A new trial suggests the medication finerenone may help protect kidney function in adults with type 1 diabetes and chronic kidney disease.

Diab Care Aug 2, 2026

Bibliometric Analysis Mapping the Evolution of Stem Cell Therapies for Diabetes Management

Orthopedics & Sports Medicine Sys. Review

Bibliometric Analysis Mapping the Evolution of Stem Cell Therapies for Diabetes Management Mapping the Growth and Trends of Stem Cell Therapy for Diabetes Research

A comprehensive review of 1,600 publications maps the evolution of stem cell and exosome therapies for Type 1 and Type 2 diabetes.

Scientists analyzed thousands of papers to track how stem cell treatments for diabetes have evolved over the last thirty years.

Frontiers Jul 24, 2026

Exercise ameliorates both type 1 and type 2 diabetes through multiple mechanisms

Diabetes & Endocrinology Sys. Review

Exercise ameliorates both type 1 and type 2 diabetes through multiple mechanisms Exercise Helps Manage Both Type 1 and Type 2 Diabetes

This narrative review summarizes how exercise improves glycemic control in both type 1 and type 2 diabetes through various mechanisms. Exerc…

Regular exercise serves as an affordable, low-risk way to help manage symptoms and complications for people living with both types of diabet…

Frontiers Jul 23, 2026

Maternal type 1 diabetes exposure associated with lower offspring risk of developing the condition

Diabetes & Endocrinology Meta-analysis

Maternal type 1 diabetes exposure associated with lower offspring risk of developing the condition Maternal type 1 diabetes may lower risk for children

Researchers analyzed the impact of maternal versus paternal type 1 diabetes on the likelihood of offspring developing the disease. The findi…

New data suggests that being in the womb while a mother has type 1 diabetes may offer long-term protection against developing the condition.

Automated insulin delivery increases time-in-range by 9.88% in young children with type 1 diabetes

Diabetes & Endocrinology Meta-analysis

Automated insulin delivery increases time-in-range by 9.88% in young children with type 1 diabetes Automated insulin delivery improves blood sugar for young children

This meta-analysis of trials and cohort studies evaluates automated insulin delivery (AID) for children under age 7 with type 1 diabetes. Th…

New data shows automated insulin systems help children under age 7 spend more time in healthy blood sugar ranges and less time at risk.

Genistein shows potential to attenuate inflammation and reduce disease severity in autoimmune conditions

Allergy & Immunology Sys. Review

Genistein shows potential to attenuate inflammation and reduce disease severity in autoimmune conditions Genistein may help reduce inflammation in several autoimmune diseases

This mini review synthesizes preclinical evidence on genistein for autoimmune diseases including SLE, RA, and type 1 diabetes. Findings sugg…

A review of genistein shows it could lower disease severity and inflammation for people with conditions like lupus and rheumatoid arthritis.

Frontiers Jul 6, 2026

Mobile-ecological momentary assessment shows 70% compliance rate among adolescents and young adults with diabetes

Diabetes & Endocrinology Meta-analysis

Mobile-ecological momentary assessment shows 70% compliance rate among adolescents and young adults with diabetes Mobile phone prompts help young people manage their daily diabetes care

This meta-analysis evaluates the use of mobile-ecological momentary assessment (mobile-EMA) in adolescents and young adults with type 1 or t…

New data shows that using mobile phones to send reminders can improve how well young people with diabetes follow their treatment plans.

Questions about Type 1 diabetes mellitus

Can cervical cancer treatment cause new Type 1 diabetes and diabetic ketoacidosis?

Yes, certain cervical cancer treatments, especially immune checkpoint inhibitors like cadonilimab, can trigger new-onset type 1 diabetes and diabetic ketoacidosis, though this is a rare but serious side effect.

Full answer →

Can integrative therapies help improve blood sugar control in Type 1 diabetes?

Integrative therapies like yoga and naturopathy may offer modest adjunctive benefits for blood sugar control in Type 1 diabetes, but evidence is limited and they should complement, not replace, standard insulin therapy.

Full answer →

All Type 1 diabetes mellitus Articles